FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending
This morning, NRx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Abbreviated New Drug Application (ANDA) for its preservative...
Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways
NexTel Medical Corp. Announces Next-Generation Wellness Product Line Incorporating FDA-Approved Pharmaceuticals
Innovative Delivery Technologies Aimed at Enhancing Bioavailability and Expanding Patient Access Beyond Traditional Injections
First National Non-GAAP EPS of $0.76 beats by $0.13, revenue of $25.29M beats by $1.02M
<![CDATA[Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fert...
<![CDATA[Pharmaceutical Executive Daily: FDA Shelves CNPV Program]]>
NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates
MIAMI, Nov. 16, 2026 (GLOBE NEWSWIRE) — NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative…
<![CDATA[Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro]]>
Neffy nasal spray for severe allergies now available without prescription
The National Association of Pharmacy Regulatory Authorities (NAPRA) classified Neffy as a Schedule II product across Canada, which means it can now be sold over the counter.
Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month
PRNewswireMumbai (Maharashtra) [India], October 1: Piramal Pharma Solutions ('PPS'), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal...
<![CDATA[FDA Grants Accelerated Approval to Rybrevant Faspro in Head and Neck Cancer]]>
Kiniksa
Kiniksa Anonymous (not verified) Mon, 10/05/2026 - 04:07 field_thread_url https://cafepharma.com/boards/threads/kiniksa.658756/ board na...
Nektar Therapeutics (NKTR) Shareholder/Analyst Call - Slideshow
Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition
The deal is designed to marry UNP’s macrocyclic peptide discovery platform with Argenx’s immunology innovation capabilities to broaden the buyer’s ability to develop oral or long-a...
Viridian Therapeutics, Inc. (VRDN) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans - Slideshow
<![CDATA[Innogen Licenses GLP-1 Therapy Efsubaglutide Alfa to Arcera]]>
<![CDATA[Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million ]]>
PFO: Rate Pressures Present Better Entry Price For This Fund
<![CDATA[Pfizer and Blackstone Sign Co-Funding Deal for berobenatide]]>
Novo Nordisk licenses Nanexa drug tech in deal worth up to €1.17 bln
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.